|Stage of funding:||Current|
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside’s proprietary microinjector.
Clearside Biomedical’s goal is to be a leading pharmaceutical company focused on the development and commercialization of therapeutics to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and retina.
The key elements of company's strategy are:
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees. The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling U.S. Army Infantry trainees at Fort Benning, GA. NDV-3A is the company’s lead development candidate to potentially treat antimicrobial resistant fungal and bacterial pathogens.
12 April 2018
30 March 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
14 March 2018